Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $VKTX
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/13/2025 | $102.00 | Sector Outperform | Scotiabank |
2/7/2025 | $38.00 | Neutral | Citigroup |
12/2/2024 | Overweight | Piper Sandler | |
11/22/2024 | $109.00 | Buy | B. Riley Securities |
11/4/2024 | $90.00 → $102.00 | Buy | H.C. Wainwright |
9/11/2024 | $80.00 | Overweight | JP Morgan |
6/27/2024 | $105.00 | Overweight | Morgan Stanley |
5/16/2024 | $115.00 → $116.00 | Outperform → Strong Buy | Raymond James |
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabo
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations
CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735.CordenPharma provides large-scale peptide manufacturing for the Dual GLP-1/GIP Receptor Agonist drug substance of VK2735.CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing for its oral peptide formulation.BASEL, Switzerland, March 11, 2025 /PRNewswire/ -- CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the sig
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply Provides Annual Capacity of Over 1 Billion Oral Tablets Viking to Make Prepayments Totaling $150 Million Between 2025-2028 SAN DIEGO, March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, an
Scotiabank initiated coverage on Viking Therapeutics with a new price target
Scotiabank initiated coverage of Viking Therapeutics with a rating of Sector Outperform and set a new price target of $102.00
Citigroup initiated coverage on Viking Therapeutics with a new price target
Citigroup initiated coverage of Viking Therapeutics with a rating of Neutral and set a new price target of $38.00
Piper Sandler initiated coverage on Viking Therapeutics
Piper Sandler initiated coverage of Viking Therapeutics with a rating of Overweight
President & CEO Lian Brian was granted 256,133 shares and sold $8,313,601 worth of shares (194,490 units at $42.75), increasing direct ownership by 3% to 2,366,570 units (SEC Form 4)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Chief Operating Officer Mancini Marianna was granted 66,200 shares and sold $2,317,599 worth of shares (54,215 units at $42.75), increasing direct ownership by 3% to 374,134 units (SEC Form 4)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Chief Financial Officer Zante Greg sold $2,150,595 worth of shares (50,309 units at $42.75) and was granted 66,200 shares, increasing direct ownership by 11% to 165,259 units (SEC Form 4)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
Viking Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
SEC Form 10-K filed by Viking Therapeutics Inc.
10-K - Viking Therapeutics, Inc. (0001607678) (Filer)
Viking Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity UnderwayStrong Year-End Cash Position of $903 MillionSAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided an update on its clinical pipeline and other corporate developments.
Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2024 on February 5, 2025
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. E
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
Amendment: SEC Form SC 13G/A filed by Viking Therapeutics Inc.
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)